Horizon2020 CARAMBA Myeloma Pipeline information sheet now available in five languagesMPE, Myeloma7 April 2021
The FDA approves the first anti-BCMA CAR-T Cell Therapy for myeloma, idecabtagene vicleucel (Abecma)Access, Myeloma31 March 2021
Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, Myeloma30 March 2021
The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, Myeloma1 March 2021
Selinexor receives positive opinion from the EMA for the treatment of refractory myelomaAccess, Myeloma30 January 2021
Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, Myeloma, Videos18 December 2020
